Mount Sinai Performs First-in-the-World Liver Cancer Treatment Using More Flexible Scheduling Approach

Newswise — NEW YORK, (April 2, 2026) –Mount Sinai Health System has become the first health system in the world to use a minimally invasive treatment system offering newly cleared by the Food and Drug Administration, that delivers radiation directly to liver tumors through the bloodstream.

The TheraSphere™ Y-90 Any Day Dosing capability within the TheraSphere 360™  Management Platform will allow doctors at Mount Sinai to treat patients on more days of the week, helping improve access and reduce time to care for patients with hepatocellular carcinoma, the most common type of liver cancer.

The first three cases were performed on Monday, March 30, under the care of Kirema Garcia-Reyes, MD, an interventional radiologist and Assistant Professor of Diagnostic, Molecular and Interventional Radiology at the Icahn School of Medicine at Mount Sinai, with contributions from Edward Kim, MD, Director of Interventional Oncology and Professor of Diagnostic, Molecular and Interventional Radiology, and Surgery, and Robert Lookstein, MD, Professor of Diagnostic, Molecular and Interventional Radiology, and Surgery, at the Icahn School of Medicine at Mount Sinai. All are leaders in interventional oncology and image-guided therapies.

As a leading center for multidisciplinary liver cancer care, the Mount Sinai Tisch Cancer Center manages highly coordinated procedures where scheduling flexibility is critical, particularly for patients who may be candidates for liver transplantation or other curative therapies.

TheraSphere Y-90 is a minimally invasive therapy that delivers radiation directly to liver tumors through the bloodstream. By targeting tumors from the inside, it helps protect healthy tissue. It is commonly used to control cancer or help patients become eligible for liver transplantation.

The Any Day Dosing capability is delivered through the TheraSphere360 Y-90 Management Platform, a digital workflow solution that supports coordination of treatment planning, dose calculation, product ordering, and case management, helping ensure timely, seamless care. At centers like the Mount Sinai Tisch Cancer Center, where specialists across multiple disciplines coordinate complex care, scheduling flexibility is especially important. Historically, radioactive decay and fixed dosing schedules limited treatment to certain days of the week. Any Day Dosing eliminates these constraints, enabling flexible scheduling, faster turnaround times, and more seamless coordination with each patient’s treatment plan.

“This is a significant milestone. With Any Day Dosing, we now have the ability to treat patients on more days of the week,” said Dr. Garcia-Reyes. “That can mean shorter wait times and more convenient scheduling during what is often a complex and time-sensitive treatment journey.”

The Mount Sinai Tisch Cancer Center continues to lead in adopting innovative technologies that enhance patient access, streamline care delivery, and improve outcomes for patients facing liver cancer.